PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
NCT07484269 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 753
Last updated 2026-03-20
Summary
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-08-01
- Primary Completion
- 2031-07-31
- Completion
- 2031-07-31
More Related Trials
-
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
NCT07054346 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer
NCT01685190 ·Status: UNKNOWN ·Phase: PHASE2
-
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer
NCT04399876 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26
NCT04746638 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
NCT06461689 ·Status: COMPLETED
-
Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
NCT06866938 ·Status: RECRUITING ·Phase: PHASE2
-
Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping
NCT00608920 ·Status: COMPLETED ·Phase: NA
-
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
NCT04346225 ·Status: RECRUITING ·Phase: PHASE2
-
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT05603559 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
NCT06943495 ·Status: RECRUITING ·Phase: PHASE1
-
68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
NCT04831307 ·Status: UNKNOWN ·Phase: NA
-
Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer
NCT06828263 ·Status: RECRUITING
-
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
NCT04443062 ·Status: COMPLETED ·Phase: PHASE2
-
Adaptive MR-guided SBRT for Localized Prostate Cancer
NCT04571762 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
NCT06391034 ·Status: RECRUITING ·Phase: PHASE2
-
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04486755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer
NCT02302105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
NCT07426094 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness
NCT03307460 ·Status: UNKNOWN ·Phase: PHASE2
-
Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer
NCT06220435 ·Status: RECRUITING ·Phase: NA
-
Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men
NCT02033447 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Adjuvant Hypofractionated Radiotherapy for Prostate Cancer
NCT06335693 ·Status: RECRUITING ·Phase: NA
-
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
NCT07096999 ·Status: RECRUITING
-
Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
NCT06355050 ·Status: NOT_YET_RECRUITING
-
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT03403595 ·Status: UNKNOWN ·Phase: PHASE1